Roche Diagnostics U.S. Media Relations
Roche will debut the Idea Lab series, where industry experts share insights on healthcare topics such as health equity, access, staffing pressures and data optimization.
INDIANAPOLIS and CHICAGO; July 22, 2022 – Roche (SIX: RO,ROG;OTCQX: RHHBY) will showcase a cutting-edge interactive and solutions-focused exhibit at the 2022 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 24-28 in Chicago.
The Roche exhibit booth (No. 2002) will feature the latest solutions that can connect laboratory systems, analyze data and drive new efficiencies so labs have more time to focus on delivering better patient care. To address current laboratory challenges, Roche will also introduce the Roche Idea Lab, where experts in areas critical to laboratory success will provide key insights. These areas include a lab’s success in health equity and testing access, staffing pressures, data optimization, and improving clinical outcomes for patients with cardiometabolic, neurodegenerative and infectious diseases.
The Roche exhibit booth will feature demonstrations of 18 innovative systems including:
cobas® pro and cobas® pure* serum work area solutions
cobas® 5800* molecular system
*Product not available for sale in the U.S. A 510(k) submission is pending with the Food and Drug Administration.
Roche will also present 11 interactive workshops as part of the Idea Lab to share best practices and provide answers on topics that matter most in today’s evolving lab environment. For more information about Roche’s participation at 2022 AACC and the Idea Lab Program, visit AACC.roche.com. Participation this year is both virtual and in-person.
Cecilia M. Thompson, M.S., Ph.D., medical director, infectious diseases, TriCore Reference Laboratories
Nam K. Tran, Ph.D., Director, pathology biorepository; professor, Division of clinical pathology, UC Davis Health
Panelists from the University of Texas Southwestern Medical Center and University of California, San Francisco
Gary Puckrien, Ph.D., president and chief executive officer, National Minority Quality Forum
Octavia Peck Palmer, Ph.D., assistant professor of critical care medicine, University of Pittsburgh School of Medicine; president-elect, American Association of Clinical Chemistry
Jennifer Lamb, system implementation program director, Roche Diagnostics
Antimicrobial stewardship in the emergency department | 3:00 - 3:45 p.m. CDT
Larissa May, M.D., director of emergency department and outpatient antibiotic stewardship, UC Davis Health; antibiotic stewardship lead, VA Northern California Healthcare System
A panel from Wisconsin Diagnostic Laboratories
Panelists from TriCore Reference Laboratories, Washington University School of Medicine and St. Louis County Sexual Health Clinic, Seattle Children’s Hospital and Massachusetts General Hospital
A panel from Roche Healthcare Consulting
Jim Poppen, system manager, laboratory, Iowa Methodist Medical Center, UnityPoint Health – Des Moines
A panel from Wisconsin Diagnostic Laboratories and UnityPoint Health
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.